JPH07112975B2 - 固型製剤 - Google Patents

固型製剤

Info

Publication number
JPH07112975B2
JPH07112975B2 JP3-512846A JP51284691A JPH07112975B2 JP H07112975 B2 JPH07112975 B2 JP H07112975B2 JP 51284691 A JP51284691 A JP 51284691A JP H07112975 B2 JPH07112975 B2 JP H07112975B2
Authority
JP
Japan
Prior art keywords
organic solvent
powder
bof
mixed
solid formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP3-512846A
Other languages
English (en)
Japanese (ja)
Other versions
JPH07112975B1 (cs
JPWO1992001453A1 (ja
Inventor
徹 西林
良博 礎
光三 石田
正則 久保
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP3-512846A priority Critical patent/JPH07112975B2/ja
Publication of JPWO1992001453A1 publication Critical patent/JPWO1992001453A1/ja
Publication of JPH07112975B1 publication Critical patent/JPH07112975B1/ja
Publication of JPH07112975B2 publication Critical patent/JPH07112975B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP3-512846A 1990-07-19 1991-07-17 固型製剤 Expired - Lifetime JPH07112975B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3-512846A JPH07112975B2 (ja) 1990-07-19 1991-07-17 固型製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2-192112 1990-07-19
JP19211290 1990-07-19
JP3-512846A JPH07112975B2 (ja) 1990-07-19 1991-07-17 固型製剤

Publications (3)

Publication Number Publication Date
JPWO1992001453A1 JPWO1992001453A1 (ja) 1993-01-14
JPH07112975B1 JPH07112975B1 (cs) 1995-12-06
JPH07112975B2 true JPH07112975B2 (ja) 1995-12-06

Family

ID=16285866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3-512846A Expired - Lifetime JPH07112975B2 (ja) 1990-07-19 1991-07-17 固型製剤

Country Status (9)

Country Link
US (1) US5316773A (cs)
EP (1) EP0489181B1 (cs)
JP (1) JPH07112975B2 (cs)
KR (1) KR0172134B1 (cs)
AU (1) AU641267B2 (cs)
DE (1) DE69122478T2 (cs)
DK (1) DK0489181T3 (cs)
ES (1) ES2093106T3 (cs)
WO (1) WO1992001453A1 (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006402B1 (ru) 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
DE10351644A1 (de) 2003-11-05 2005-06-09 Bayer Technology Services Gmbh Verfahren zur Herstellung von lagerstabilen multiplen Emulsionen
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
US9791445B2 (en) 2013-01-28 2017-10-17 Kansas State University Research Foundation Rift Valley Fever Virus glycoproteins, Gn and Gc, and their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430684A (en) * 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS5899411A (ja) * 1981-12-05 1983-06-13 Shoichiro Ozaki 制ガン剤
JPS58109411A (ja) * 1981-12-23 1983-06-29 Shionogi & Co Ltd ニフエジピン固型製剤組成物
US4864021A (en) * 1984-10-30 1989-09-05 Otsuka Pharmaceutical Co., Ltd. 5-fluorouracil derivatives
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
JPS63201127A (ja) * 1987-02-17 1988-08-19 Otsuka Pharmaceut Co Ltd ５−フルオロウラシル誘導体を含有する制癌剤
DK169520B1 (da) * 1986-07-25 1994-11-21 Otsuka Pharma Co Ltd 5-fluoruracilderivater, fremgangsmåde til deres fremstilling, anticancerpræparat indeholdende et sådant derivat og anvendelse af et sådant derivat til fremstilling af et præparat til behandling af cancer
JPS63115817A (ja) * 1986-11-04 1988-05-20 Mitsubishi Kasei Corp 肝疾患治療薬組成物
DE3877331T2 (de) * 1987-11-11 1993-05-27 Pharmascience Lab Exifon und ein wasserloesliches polymer enthaltende pharmazeutische zubereitung.
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
WO1990007334A1 (fr) * 1989-01-05 1990-07-12 Otsuka Pharmaceutical Co., Ltd. Agent carcinostatique non injecte permettant de supprimer l'inflammation due a 5-fluorouracil, et procede de traitement du cancer
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament

Also Published As

Publication number Publication date
EP0489181B1 (en) 1996-10-02
JPH07112975B1 (cs) 1995-12-06
AU8219091A (en) 1992-02-18
EP0489181A4 (en) 1992-09-30
KR920702221A (ko) 1992-09-03
EP0489181A1 (en) 1992-06-10
DE69122478T2 (de) 1997-05-28
KR0172134B1 (ko) 1999-02-01
AU641267B2 (en) 1993-09-16
US5316773A (en) 1994-05-31
DK0489181T3 (da) 1996-11-18
WO1992001453A1 (fr) 1992-02-06
DE69122478D1 (de) 1996-11-07
ES2093106T3 (es) 1996-12-16

Similar Documents

Publication Publication Date Title
US7799860B2 (en) Composition improved in the solubility or oral absorbability
KR0136279B1 (ko) 일정수분을 함유하는 서방형 제제
SK283572B6 (sk) Farmaceutická kompozícia vo forme tuhej disperzie obsahujúca askomycín
WO1997004782A1 (en) Solid dispersion or solid dispersion preparation of xanthine derivatives
JPH07291854A (ja) 溶解性の改善された医薬品製剤
CN101600419A (zh) 含有瑞伐拉赞的固体分散体以及其制备方法
KR101394121B1 (ko) 3-｛5-[4-(시클로펜틸옥시)-2-하이드록시벤조일]-2-[(3-하이드록시-1,2-벤즈이소옥사졸-6-일)메톡시]페닐｝프로피온산 또는 그 염을 함유하는 경구용 조성물
MXPA06000370A (es) Dispersion solida de tacrolimus.
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
JP2004131393A (ja) 易溶出性製剤
EP0954288A1 (en) Solid solution of an antifungal agent with enhanced bioavailability
US20110288045A1 (en) Wet granulation of tenofovir, emtricitabine and efavirenz
US20050053669A1 (en) Administration form for the oral application of poorly soluble acidic and amphorteric drugs
CN102149715A (zh) 肝适能的稳定化固态分散物及其制备方法
JPH09501150A (ja) カプセル製剤
JP4210355B2 (ja) 固形製剤組成物
JPH07112975B2 (ja) 固型製剤
JPWO1992001453A1 (ja) 固型製剤
KR100267525B1 (ko) 시타라빈 옥포스페이트 경질 캡슐제
EA015440B1 (ru) Твердая лекарственная форма, содержащая полиморфную форму 1 клопидогрела гидросульфата
JPH05139973A (ja) ニフエジピン含有固形製剤の製造方法
JPH0776516A (ja) 難溶性薬物含有製剤の製造方法
JPH07112934A (ja) ペントキシフィリンの徐放化製剤およびその製法
CN112843066B (zh) 具良好溶解度的含吡唑并嘧啶衍生物的组合物及其应用
JPH11130663A (ja) 水難溶性成分を配合した固形剤